💬In plain words
What the trial is, and whether it could suit you
This lay description has been written in conjunction with, and the content approved by our Patient and Public Involvement collaborators. Patients with kidney cachexia will experience extreme muscle loss, reduced strength and symptoms including fatigue, reduced appetite and lower quality of life. Patients are also at an increased risk of hospitalisation and shortened life expectancy. Previous research suggests that treatments that target several causes of the muscle wasting syndrome (known as cachexia), show better outcomes for patients than treatments using just one method (for example only exercise). The investigators want to see if combining different treatments (exercise, dietary advice and anti-inflammatory supplements) will improve outcomes for patients with kidney failure receiving haemodialysis at risk of developing kidney cachexia, compared to patients who only receive routine ki
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
* CKD Stage 5 patients receiving maintenance HD therapy for \>3 months
* Oedema-free weight loss of at least 5% in 12 months or BMI less than 20 kg/m2
* Self-reported decreased physical function/muscle strength and appetite, increased fatigue
* Male or female, aged \>18 years and
* Able to provide written informed consent.
Exclusion Criteria:
* Under 18 years of age
* Patients within 3 months of initiation of HD (patients in this time frame are generally less clinically stable, many having vascular access procedures performed and with much higher rates of intercurrent events, including death and hospitalisation)
* Patients experiencing weight loss due to clinically explainable reasons for example malabsorption or oesophageal blockage
* Patients already receiving chronic anticoagulation therapy or with a history of bleeding with 3 months/active bleeding issues
* Patients receiving immunosuppressants or immunomodulators
* Patients who are pregnant or breast feeding
* Patients with a hypersensitivity to any of the constituent components of the omega-3 dietary supplement
* Patients who have dementia, a psychiatric disorder (who are not treated and stable) or a severe cognitive impairment which would deem them unable to give informed consent
* Patients with expected survival on dialysis of \<6 months \[e.g. those with severe heart failure (New York Heart Association ≥3)\]
* Patients for whom dialysis withdrawal is being considered
* Patients likely to receive a live-donor transplant or transfer to peritoneal dialysis during the study duration
* Patients with bilateral lower limb amputations
* Patients deemed to be clinically unstable by their treating physician
* Patients who are non-English speaking (not having the ability to provide informed consent, read and write English)
* Patients who are currently enrolled in any study which involves exercise, fish oil/omega-3 or have been taking fish oil or omega-3 supplementation in the previous 3 months
* Patients who are not able/willing to be involved.
HealthTeky